BSX
Boston Scientific Corporation
NYSE · USHealthcareMedical - Devices
$43.77-0.59%
Price as of Jul 20, 2026
BSX financials
Boston Scientific Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $20.1B | $16.7B | $14.2B | $12.7B |
| Cost of revenue | $6.2B | $6.5B | $5.4B | $5.0B |
| Gross profit | $13.9B | $10.3B | $8.8B | $7.7B |
| Operating expenses | $9.9B | $7.6B | $6.7B | $5.9B |
| Operating income | $4.0B | $2.6B | $2.2B | $1.8B |
| Net income | $2.9B | $1.9B | $1.6B | $698.0M |
| EBITDA | $5.1B | $3.9B | $3.5B | $2.7B |
| Basic EPS | $1.96 | $1.26 | $1.08 | $0.45 |
| Diluted EPS | $1.94 | $1.25 | $1.07 | $0.45 |
| Balance sheet | ||||
| Cash & equivalents | $2.0B | $414.0M | $865.0M | $928.0M |
| Total assets | $43.7B | $39.4B | $35.1B | $32.5B |
| Total liabilities | $19.2B | $17.4B | $15.6B | $14.9B |
| Stockholders’ equity | $24.2B | $21.8B | $19.3B | $17.6B |
| Total debt | $12.4B | $11.1B | $9.5B | $9.3B |
| Net debt | $10.4B | $10.7B | $8.6B | $8.4B |
| Cash flow | ||||
| Operating cash flow | $4.5B | $3.4B | $2.5B | $1.5B |
| Capital expenditure | -$876.0M | -$790.0M | -$800.0M | -$612.0M |
| Free cash flow | $3.7B | $2.6B | $1.7B | $914.0M |
| Dividends paid | $0.00 | $0.00 | -$28.0M | -$55.0M |
| Share repurchases | $0.00 | $0.00 | $0.00 | $136.0M |